Coya Therapeutics annual operating margin
2023
2024
2025
Coya Therapeutics's operating margin was −283.87% for fiscal 2025.
View full Coya Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −283.87% | +201.49 pp |
| 2024 | 2024-12-31 | −485.35% | −353.68 pp |
| 2023 | 2023-12-31 | −131.67% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −2,891.13% | +1029.34 pp |
| Q1 2026 | 2026-03-31 | −3,042.13% | −65.24 pp |
| Q4 2025 | 2025-12-31 | −152.30% | +208879.21 pp |
| Q3 2025 | 2025-09-30 | −68.26% | +26.22 pp |
| Q2 2025 | 2025-06-30 | −3,920.47% | +402.37 pp |
| Q1 2025 | 2025-03-31 | −2,976.89% | −3007.13 pp |
| Q4 2024 | 2024-12-31 | −209,031.51% | — |
| Q2 2024 | 2024-06-30 | −94.48% | — |
| Q1 2024 | 2024-03-31 | −4,322.84% | — |
| Q4 2023 | 2023-12-31 | 30.24% | — |
Across the available reported history, Coya Therapeutics's operating margin increased from −485.35% to −283.87%, a change of +201.49 percentage points. The latest reported quarter, Q2 2026, shows −2,891.13%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Coya Therapeutics filings at SEC.gov ↗